Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)
Taisho Pharmaceutical Holdings Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Tokyo, JP. The stock last traded at $14.00, up 16.67% on the session, giving a market capitalisation of $18.13B. On trailing twelve-month figures it carries a trailing P/E of 2.37, a net margin of 6.3%. Its beta of 0.44 implies it has historically moved less than the broad market.
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare entity engaged in the comprehensive process of researching, developing, manufacturing, marketing, distributing, and selling both over-the-counter (OTC) and prescription pharmaceutical products. The company operates across Japan and internationally, structuring its diverse activities into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group concentrates on consumer health, offering an extensive selection of non-prescription drugs, quasi-pharmaceuticals, nutritional products, and general medical and hygiene supplies. Its prominent brands encompass the popular Lipovitan range of energy drinks; the Pabron series for cold and sinus relief; RiUP products designed for hair re-growth; Taisho Kampo, specializing in gastrointestinal treatments; Colac laxatives; Naron and other antipyretic analgesics; Preser for hemorrhoid care; and a variety of international antipyretic analgesics such as Hapacol, Efferalgan, Dafalgan, and Tempra. This segment also provides Counterpain topical anti-inflammatory pain relievers, Vitacilina for dermatological conditions, and VICKS cough suppressant throat lozenges and medicated drops. Beyond its healthcare product offerings, this group manages ventures in real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Operation Group is dedicated to ethical drugs. Its portfolio includes Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, another bisphosphonate medication for osteoporosis; Lusefi, a treatment for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This division is actively engaged in developing new pharmaceuticals, particularly focusing on therapeutic areas such as central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic complaints. Additionally, Taisho Pharmaceutical supplies essential raw materials for both pharmaceutical and quasi-drug production, and markets a range of health foods and skincare products. The company, which traces its origins back to 1912, is headquartered in Tokyo, Japan.
Taisho Pharmaceutical Holdings Co., Ltd. is most often compared with the following Healthcare names: